S

Soligenix
D

SNGX

3.40000
USD
0.12
(3.66%)
Market Closed
Volume
403
EPS
-7
Div Yield
-
P/E
-1
Market Cap
8,532,297
Related Instruments
    A
    ALT
    -0.85500
    (-10.11%)
    7.60000 USD
    I
    INO
    -0.54000
    (-11.25%)
    4.26000 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    S
    SNES
    -0.16000
    (-5.99%)
    2.51000 USD
    V
    VBIV
    0
    (0%)
    0.000000 USD
    V
    VXRT
    -0.05030
    (-7.97%)
    0.58050 USD
    More
News

Title: Soligenix Inc.

Sector: Healthcare
Industry: Biotechnology
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).